Efficacy of drug treatment for severe melioidosis and eradication treatment of melioidosis: A systematic review and network meta-analysis
PLOS Neglected Tropical Diseases · 12.06.2023 · 17 (6) · e0011382
DOI: 10.1371/journal.pntd.0011382 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 12.06.2023. Verfasst von Thunyarat Anothaisintawee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bacterial and Parasitic Diseases, US Army Medical Directorate of the Armed Forces Research Institute of Medical Sciences, Bangkok, Thai…. Hauptthemen laut MEDLINE: Melioidosis, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: Defense Threat Reduction Agency.
Abstract (Originalsprache)
Background
This systematic review and network meta-analysis (NMA) aimed to compare the efficacy of all available treatments for severe melioidosis in decreasing hospital mortality and to identify eradication therapies with low disease recurrence rates and minimal risk of adverse drug events (AEs). Methodology Relevant randomized controlled trials (RCT) were searched from Medline and Scopus databases from their inception until July 31, 2022. RCTs that compared the efficacy between treatment regimens for severe melioidosis or eradication therapy of melioidosis, measured outcomes of in-hospital mortality, disease recurrence, drug discontinuation, or AEs, were included for review. A two-stage NMA with the surface under the cumulative ranking curve (SUCRA) was used to estimate the comparative efficacy of treatment regimens. Principal findings Fourteen RCTs were included in the review. Ceftazidime plus granulocyte colony-stimulating factor (G-CSF), ceftazidime plus trimethoprim-sulfamethoxazole (TMP-SMX), and cefoperazone-sulbactam plus TMP-SMX had a lower mortality rate than other treatments and were ranked as the top three most appropriate treatments for severe melioidosis with the SUCRA of 79.7%, 66.6%, and 55.7%, respectively. However, these results were not statistically significant. For eradication therapy, treatment with doxycycline monotherapy for 20 weeks was associated with a significantly higher risk of disease recurrence than regimens containing TMP-SMX (i.e.,TMP-SMX for 20 weeks, TMP-SMX plus doxycycline plus chloramphenicol for more than 12 weeks, and TMP-SMX plus doxycycline for more than 12 weeks). According to the SUCRA, TMP-SMX for 20 weeks was ranked as the most efficacious eradication treatment (87.7%) with the lowest chance of drug discontinuation (86.4%), while TMP-SMX for 12 weeks had the lowest risk of AEs (95.6%).
Conclusion
Our results found a non-significant benefit of ceftazidime plus G-CSF and ceftazidime plus TMP-SMX over other treatments for severe melioidosis. TMP-SMX for 20 weeks was associated with a lower recurrence rate and minimal risk of adverse drug events compared to other eradication treatments. However, the validity of our NMA may be compromised by the limited number of included studies and discrepancies in certain study parameters. Thus, additional well-designed RCTs are needed to improve the therapy of melioidosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Bacterial and Parasitic Diseases, US Army Medical Directorate of the Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.
- Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
ORCID-Profile: Thunyarat Anothaisintawee
Förderung
- Defense Threat Reduction Agency
Zitieren
APA
Anothaisintawee, T., Harncharoenkul, K., Poramathikul, K., Phontham, K., Boonyarangka, P., Kuntawunginn, W., Spring, M., Boudreaux, D., Livezey, J., & Chantratita, N. (2023). Efficacy of drug treatment for severe melioidosis and eradication treatment of melioidosis: A systematic review and network meta-analysis. PLOS Neglected Tropical Diseases, 17(6), e0011382. https://doi.org/10.1371/journal.pntd.0011382
Vancouver
Anothaisintawee T, Harncharoenkul K, Poramathikul K, Phontham K, Boonyarangka P, Kuntawunginn W, et al. Efficacy of drug treatment for severe melioidosis and eradication treatment of melioidosis: A systematic review and network meta-analysis. PLOS Neglected Tropical Diseases. 2023;17(6):e0011382. doi:10.1371/journal.pntd.0011382
BibTeX
@article{Anothaisintawee2023,
author = {Anothaisintawee, Thunyarat and Harncharoenkul, Krit and Poramathikul, Kamonporn and Phontham, Kittijarankon and Boonyarangka, Parat and Kuntawunginn, Worachet and Spring, Michele and Boudreaux, Daniel and Livezey, Jeffrey and Chantratita, Narisara},
title = {Efficacy of drug treatment for severe melioidosis and eradication treatment of melioidosis: A systematic review and network meta-analysis},
journal = {PLOS Neglected Tropical Diseases},
year = {2023},
volume = {17},
number = {6},
pages = {e0011382},
doi = {10.1371/journal.pntd.0011382}
}
EUVIMED